Possible dose-side effect relationship of antipsychotic drugs: Relevance to cognitive function in schizophrenia

Expert Review of Clinical Pharmacology

Volumn 1, Issue 6, 2008, Pages 791-802

  Sumiyoshi, Tomiki ^a,b  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

5 HT1A receptor; Atypical antipsychotic drug; Cognition; Dose dependence; Extrapyramidal sign; Schizophrenia; Serotonin receptor; Typical antipsychotic drug

Indexed keywords

5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BIFEPRUNOX; BLONANSERIN; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LURASIDONE; MELPERONE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RISPERIDONE; SSR 181507; TANDOSPIRONE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; ATTENTION; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GLUCOSE INTOLERANCE; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MEMORY DISORDER; METABOLIC DISORDER; METABOLIC SYNDROME X; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; PARKINSONISM; PROTEIN FUNCTION; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VERBAL BEHAVIOR; VERBAL MEMORY; WEIGHT GAIN; WORKING MEMORY;

EID: 70049094786     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.6.791     Document Type: Review

References (108)

1. Meltzer HY, Sumiyoshi T. Les nouveaux antipsychotiques; perspective clinique. In: Medicaments Antipsychotiques: Evolution ou Revolution? Olie J-P, Dalery J, Azorin J-M (Eds). Paris, France 63-90 (2001).
2. Sadock BJ, Sadock VA, Sussman N. Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment (4th Edition). Lippincott Williams & Wilkins, Inc., PA, USA (2006).
3. Miyamoto S, Merrill DB, Lieberman JA et al. Antipsychotic drugs. In: Psychiatry (3rd Edition). Tasman A, Kay J, Lieberman JA, First MB, Maj M (Eds). John Wiley & Sons, Ltd, Chichester, UK 2161-2201 (2008).
4. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160(2), 492-494 (1966).
5. high states, implying many paths to psychosis. Proc. Natl Acad. Sci. USA 102(9), 3513-3518 (2005).
6. high dopamine receptors. Synapse 60(4), 319-346 (2006).
7. 4 receptors elevated in schizophrenia. Nature 365, 441-445 (1993).
8. 3H] raclopride binding in postmortem caudate of subjects with schizophrenia or major depression. Brain Res. 681, 109-116 (1995).
9. 2-dopamine receptors in drug-naive schizophrenia. Science 234, 1558-1563 (1986).
10. 2 receptors in rats with excitotoxic damage of the entorhinal cortex, an animal model of schizophrenia. Brain Res. Mol. Brain Res. 140(1-2), 116-119 (2005).
11. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188(4194), 1217-1219 (1975).
12. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261(5562), 717-719 (1976).
13. 2 receptor in schizophrenia. Expert Opin. Ther. Targets 10(4), 515-531 (2006).
14. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8(7), 539-554 (2007).
15. Meltzer HY. The significance of serotonin for neuropsychiatric disorders. J. Clin. Psychiatry 52, 70-72 (1991).
16. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(7), 1159-1172 (2003).
17. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology (8th Edition). Oxford University Press, Oxford, UK (2003).
18. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112, S35-S39 (1993).
19. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708, 209-214 (1996).
20. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15(5), 442-455 (1996).
21. 2 pKi values. J. Pharmacol. Exp. Ther. 251(1), 238-246 (1989).
22. 2 receptors. J. Pharmacol. Exp. Ther. 266(3), 1374-1384 (1993).
23. 2 receptor binding of antipsychotics in vivo. Pharmacol. Biochem. Behav. 49(1), 165-169 (1994).
24. 2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav. 47(3), 553-557 (1994).
25. 2 receptor occupancy rates by haloperidol and clozapine in vivo. Jpn. J. Psychiatry Neurol. 47(1), 131-137 (1993).
26. 2 receptor occupancy. Neuropsychopharmacology 12(1), 57-64 (1995).
27. Araki T, Yamasue H, Sumiyoshi T et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(2), 204-208 (2006).
28. Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int. J. Neuropsychopharmacol. 9(6), 677-683 (2006).
29. Sumiyoshi T, Jayathilake K, Meltzer HY. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr. Res. 59(1), 7-16 (2003).
30. Sumiyoshi T, Jayathilake K, Meltzer HY. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophr. Res. 62(1-2), 65-72 (2003).
31. Murasaki M, Nishikawa H, Ishibashi T. Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn. J. Clin. Psychopharmacol. 11, 845-854 (2008).
32. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J. Clin. Psychopharmacol. 24(3), 345-348 (2004).
33. Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. J. Clin. Psychopharmacol. 24(4), 452-454 (2004).
34. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005).
35. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618), 1085-1097 (2008).
36. Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case - control study. BMJ 325(7358), 243 (2002).
37. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159(4), 561-566 (2002).
38. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 62(2), 92-100 (2001).
39. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22(7), 841-852 (2002).
40. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 44(8), 778-783 (1998).
41. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49, 538-544 (1992).
42. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157(4), 514-520 (2000).
43. 2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31(9), 1854-1863 (2006).
44. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61, 123-136 (2003).
45. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry 56, 749-754 (1999).
46. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 57(6), 688-691 (2005).
47. Nieuwenstein MR, Aleman A, de Haan EH. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J. Psychiatr. Res. 35(2), 119-125 (2001).
48. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153(3), 321-330 (1996).
49. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 45(3), 175-184 (2000).
50. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin. Neurosci. 61(6), 602-609 (2007).
51. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(1), 280-287 (2008).
52. Sumiyoshi C, Matsui M, Sumiyoshi T, Yamashita I, Sumiyoshi S, Kurachi M. Semantic structure in schizophrenia as assessed by the category fluency test: effect of verbal intelligence and age of onset. Psychiatry Res. 105(3), 187-199 (2001).
53. Sumiyoshi C, Sumiyoshi T, Matsui M et al. Effect of orthography on the verbal fluency performance in schizophrenia: examination using Japanese patients. Schizophr. Res. 69(1), 15-22 (2004).
54. Sumiyoshi C, Sumiyoshi T, Nohara S et al. Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophr. Res. 74(1), 91-100 (2005).
55. Sumiyoshi C, Ertugrul A, Anil Yagcioglu AE. Semantic memory deficits based on category fluency performance in schizophrenia: similar impairment patterns of semantic organization across Turkish and Japanese patients. Psychiatry Res. (2009) (In Press).
56. Meltzer HY, Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry 53(3), 265-267 (2003).
57. Sumiyoshi T, Meltzer HY. Relapse in schizophrenia. In: Psychiatry Highlights 2001-02. Lader M (Ed.). Health Press, Oxford, UK 27-35 (2002).
58. 1A receptor agonism. Brain Res. 1023(1), 54-63 (2004).
59. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26(3), 325-339 (2002).
60. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76(5), 1521-1531 (2001).
61. Kuroki H, Meltzer HY, Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontalcortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288, 774-781 (1998).
62. Parada MA, Hernandez L, Puig de Parada M, Rada P, Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281, 582-588 (1997).
63. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl.) 169(3-4), 404-411 (2003).
64. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161(6), 985-995 (2004).
65. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do clozapine and risperidone affect social competence and problem solving? Am. J. Psychiatry 161(2), 364-367 (2004).
66. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64(6), 633-647 (2007).
67. Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164(7), 1061-1071 (2007).
68. Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr. Res. 101(1-3), 320-330 (2008).
69. Sumiyoshi T, Higuchi Y, Kawasaki Y et al. Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(7), 1299-1303 (2006).
70. Sumiyoshi T, Roy A, Kim CH et al. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology (Berl.) 177(1-2), 79-83 (2004).
71. 1A agonist, on memory function in schizophrenia. Biol. Psychiatry 49(10), 861-868 (2001).
72. Sumiyoshi T, Matsui M, Yamashita I et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J. Clin. Psychopharmacol. 20(3), 386-388 (2000).
73. 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95(1-3), 158-168 (2007).
74. Sumiyoshi T, Higuchi Y, Ito T et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res. Neuroimag. (2009) (In Press).
75. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry 64, 1115-1122 (2007).
76. Green MF, Marshall BD Jr, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 154, 799-804 (1997).
77. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34, 702-712 (1993).
78. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37, 1-11 (1999).
79. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch. Gen. Psychiatry 63(11), 1189-1197 (2006).
80. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol. Psychiatry 62(7), 818-821 (2007).
81. Sumiyoshi T, Kawasaki Y, Suzuki M, Higuchi Y, Kurachi M. Neurocognitive assessment and pharmacotherapy towards prevention of schizophrenia: what can we learn from first episode psychosis? Clin. Psychopharmacol. Neurosci. 6(2), 57-64 (2008).
82. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 89(1-3), 211-224 (2007).
83. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25(2), 233-255 (1999).
84. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158(2), 176-184 (2001).
85. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25, 201-222 (1999).
86. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 457-472 (2005).
87. Woodward ND. A meta-analysis of neuropsychological change with second generation antipsychotics in schizophrenia. Presented at: 24th CINP Congress. Chicago, IL, USA 12 July 2006
88. 1A receptor activation. Brain Res. 1043(1-2), 32-41 (2005).
89. 1A receptors in the modulation of stress-induced lactate metabolism in the medial prefrontal cortex and basolateral amygdala. Psychopharmacology (Berl.) 186(2), 218-225 (2006).
90. Sumiyoshi T, Matsui M, Itoh H et al. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res. 157(1-3), 87-93 (2008).
91. Sumiyoshi T, Matsui M, Nohara S et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 158(10), 1722-1725 (2001).
92. 1A receptors in memory function. Am. J. Psychiatry 161(8), 1505 (2004).
93. 1A receptors on human explicit memory. Am. J. Psychiatry 160(2), 334-340 (2003).
94. 1A receptors improve cognition in schizophrenia? Behav. Brain Res. 195(1), 98-102 (2008),
95. Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J. Clin. Psychopharmacol. 13(3), 204-209 (1993).
96. Poyurovsky M, Weizman A. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int. Clin. Psychopharmacol. 12(5), 263-268 (1997).
97. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 59(10), 921-928 (2002).
98. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163(5), 790-799 (2006).
99. Sumiyoshi T. Neurocognitive assessment and pharmacotherapy: towards prevention of psychosis. First episode psychosis: integrating neurobiological and psychosocial determinants of outcome Presented at: 62nd Annual Meeting of Society of Biological Psychiatry. San Diego, CA, USA, 17-19 May 2007.
100. Sumiyoshi T, Kawasaki Y, Higuchi Y, Matsui M, Suzuki M, Kurachi M. Neurocognitive assessment and pharmacotherapy: towards prevention of psychosis. First episode psychosis: integrating neurobiological and psychosocial determinants of outcome. Presented at: 2nd International Congress of Biological Psychiatry. Santiago, Chile, 17-21 April 2007.
101. Hagan JJ, Jones DN. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31(4), 830-853 (2005).
102. Meltzer HY, Sumiyoshi T, Jayathilake K. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res. 105(3), 201-209 (2001).
103. Miyake N, Miyamoto S, Takeuchi A et al. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: a randomized, double-blind comparison with risperidone. Jpn. J. Clin. Psychopharmacol. 11, 315-326 (2008).
104. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 341-356 (2005).
105. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 186(2), 197-207 (2008).
106. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 572(2-3), 160-170 (2007).
107. Goldstein JM. Atypical antipsychotic drugs: beyond acute psychosis, new directions. Expert Opin. Emerg. Drugs 4(1), 127-151 (1999).
108. Ishibashi T, Horisawa T, Yabuuchi K, Tagashira R, Ohno Y. Receptor binding characteristics of SM-13496, a novel atypical antipsychotic agent. Soc. Neurosci. Abstr. 894, 7 (2002).